Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 160 • 2020 Pediatric Rheumatology Symposium
CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis
Vincent Giacalone ¹, Alexandre Cammarata-Mouchtouris ¹, Diego Mauricio Moncada Giraldo ¹, Sreekala Shenoy ¹, Lori Ponder ¹, Talia Gergely ², Patricia Vega-Fernandez ³, Cynthia Manos ⁴, Elaine Flanagan ¹, Rabindra Tirouvanziam ¹ and Sampath Prahalad⁵, ¹emory university, atlanta, ²Emory University School of Medicine, Atlanta, ³Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Children's Healthcare of Atlanta, Atlanta, ⁵Emory + Children's Pediatric Institute, Atlanta
Background/Purpose: Rationale: Juvenile idiopathic arthritis (JIA) is an inflammatory autoimmune disorder driven by dysfunction of the joint tissue and abnormal immune responses. As deep phenotyping…
Abstract Number: 004 • 2020 Pediatric Rheumatology Symposium
Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort
Jennifer Lee¹, Simon Eng ², Brian Feldman ³, Jaime Guzman ⁴, Kiem Oen ² and Rae Yeung ³, ¹University of Toronto, Toronto, Canada, ²Toronto, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of British Columbia and BC Children's Hospital, Vancouver, Canada
Background/Purpose: PRINTO recently proposed preliminary JIA classification criteria to revise the International League of Associations for Rheumatology (ILAR) criteria. The stated aim was to obtain…
Abstract Number: 074 • 2020 Pediatric Rheumatology Symposium
Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)
Ming Min ¹, Catherine Gibson ², Mark Friswell³, Tania Crotti ⁴ and Christina Boros ⁵, ¹Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, North Adelaide, South Australia, Australia, ²Women's and Children's Health Network, North Adelaide, South Australia, Australia, ³Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, South Australia, Australia, ⁴Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia, ⁵Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, Australia
Background/Purpose: Patient outcomes and experiences are key components in the measurement of overall health outcomes in JIA and can be measured by validated PROMs and…
Abstract Number: 164 • 2020 Pediatric Rheumatology Symposium
The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants
Kaiyu Jiang ¹, Yungki Park ², tao liu ³, Marc Sudman ⁴, Susan Thompson ⁵ and James Jarvis⁶, ¹University at Buffalo, Buffalo, ²University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, ³Roswell Park Cancer Institute, Buffalo, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, ⁶University at Buffalo Jacobs School of Medicine, Buffalo
Background/Purpose: The JIA risk haplotypes, like those of other autoimmune diseases, are highly enriched for H3K4me1/H3K27ac histone marks, epigenetic features typically associated with functional enhancers.…
Abstract Number: 014 • 2020 Pediatric Rheumatology Symposium
Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis
Dirk Foell¹, Carolin Park ², Linda Ziegler ², Dirk Holziner ³, Kirsten Minden ⁴, Renato Cotti ⁵ and Jakob Weber ⁵, ¹University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, ²University of Muenster, Muenster, Germany, ³University of Essen, Essen, Germany, ⁴Berlin, Germany, ⁵Buehlmann Laboratories, Schoenenbuch, Switzerland
Background/Purpose: Treat-to-target strategies are established for the therapeutic approach to patients suffering from juvenile idiopathic arthritis (JIA). Another proposed therapeutic concept in pediatric rheumatology involves…
Abstract Number: 086 • 2020 Pediatric Rheumatology Symposium
Advanced Multidisciplinary Care: A New Approach to Childhood Arthritis
Julia Brooks¹, Dorothy Adams ², Robin Hellweg ¹, Maggie Mercer ¹, Joni Shair ², Dwaraka Veeramreddy ³, Aynsley Wennberg ¹ and Heinrike Schmeling ⁴, ¹Alberta Children's Hospital, Calgary, Alberta, Canada, ²Alberta Children's Hospital, Calgary, Canada, ³Alberta Children's Hospital/University of Calgary, Calgary, Canada, ⁴Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada
Background/Purpose: Many patients are overwhelmed with the diagnosis of chronic childhood arthritis and require long-term treatments. Our objective was to develop a new, child and…
Abstract Number: 165 • 2020 Pediatric Rheumatology Symposium
A Massively Parallel Reporter Assay Screen of Genetic Variants on JIA Haplotypes Reveals Variants Associated with Altered Function of an Intergenic Enhancer in the HLA Class II Locus
Kaiyu Jiang ¹, tao liu ², Ryan Tewhey ³ and James Jarvis⁴, ¹University at Buffalo, Buffalo, ²Roswell Park Cancer Institute, Buffalo, ³Jackson Laboratories, Bar Harbor, ⁴University at Buffalo Jacobs School of Medicine, Buffalo
Background/Purpose: While genome-wide association studies have provided valuable information about genetic risk for juvenile idiopathic arthritis (JIA), we are still unable to determine the actual…
Abstract Number: 017 • 2020 Pediatric Rheumatology Symposium
MyD88 S209R-Mediated Immune Dysregulation in Mouse Models of Arthritis
Sufia Bakshi¹, Malika Waschmann ², Anders Lindstedt ², Emily Rominger ², Robert Colbert ³ and Keith Sikora ⁴, ¹National Institutes of Health, Bethesda, Maryland, ²National Institutes of Health, Bethesda, ³NIH/NIAMS, Bethesda, Maryland, ⁴National Institutes of Health Clinical Center, Bethesda, Maryland
Background/Purpose: MYD88 is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-kB. We previously reported a heterozygous de novo mutation in MYD88 (S222R)…
Abstract Number: 097 • 2020 Pediatric Rheumatology Symposium
A Pilot Randomized Controlled Trial of the iCanCope Pain Self-management Application for Adolescents with Juvenile Idiopathic Arthritis
Chitra Lalloo ¹, Lauren Harris ², Amos Hundert ², Roberta Berard ³, Joseph Cafazzo ⁴, Mark Connelly ⁵, Brian Feldman ², Kristin Houghton ⁶, Adam Huber ⁷, Ronald Laxer ⁸, Nadia Luca ⁹, Heinrike Schmeling ¹⁰, Lynn Spiegel ¹¹, Lori Tucker ¹², Quynh Pham ⁴, Cleo Davies-Chalmers ¹³ and Jennifer Stinson¹⁴, ¹The Hospital for Sick Children, Toronto, Ontario, Canada, ²The Hospital for Sick Children, Toronto, Canada, ³Children's Hospital London Health Sciences Centre, London, Canada, ⁴University of Toronto, Toronto, Canada, ⁵Kansas City, ⁶University of British Columbia - Vancouver, Vancouver, Canada, ⁷IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁸The Hospital for Sick Children and University of Toronto, Toronto, Canada, ⁹University of Calgary, Calgary, Alberta, Canada, ¹⁰Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada, ¹¹University of Toronto/Hospital for Sick Children, Thornhill, Canada, ¹²BC Children's Hospital, Vancouver, British Columbia, Canada, ¹³The Hospital for Sick Children, Toonto, Canada, ¹⁴University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada
Background/Purpose: Pain is the most common symptom of Juvenile Idiopathic Arthritis (JIA), a chronic childhood illness that has potentially debilitating effects on health-related quality of…
Abstract Number: 167 • 2020 Pediatric Rheumatology Symposium
Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment
Melissa Elder ¹, Luciana Paim marques², Akaluck Thatayatikom ¹, John Bowden ², Bianca da SIlva ² and Juan Aristizabal ², ¹University of Florida, Gainesville, ²University of Florida, Gainesville, Florida
Background/Purpose: Metabolomic and lipidomic pathways serve as key sensors and effectors of genetic, epigenetic, and environmental factors that shape the development and function of the…
Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium
Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis
Ryan Funk¹ and Mara Becker ², ¹University of Kansas, Leawood, Kansas, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill
Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
Abstract Number: 101 • 2020 Pediatric Rheumatology Symposium
Uveitis Treatment in the CARRA II Registry: Tumor Necrosis Factor-inhibitors and Beyond
Mona Riskalla¹, Fatima Barbar-Smiley ², Michael Shyne ¹ and Melissa Lerman ³, ¹University of Minnesota, Minneapolis, Minnesota, ²Nationwide Children's Hospital, Columbus, Ohio, ³Philadelphia, Pennsylvania
Background/Purpose: Uveitis associated with JIA (JIA-U) is the most common extra-articular complication of JIA. As JIA-U is associated with significant risk of visual loss and…
Abstract Number: 171 • 2020 Pediatric Rheumatology Symposium
Development and Acceptability of an Adolescent Self-management Program for Juvenile Idiopathic Arthritis
Kelsey Chomistek¹, Cheryl Barnabe ², Katie Birnie ³, Julia Brooks ⁴, Tracey Clancy ⁵, Syeda Farwa Naqvi ⁵, Nadia Luca ⁵, Maggie Mercer ⁴, Maria Santana ⁵, Jennifer Stinson ⁶, Aynsley Wennberg ⁴ and Heinrike Schmeling ⁷, ¹Calgary, Alberta, Canada, ²University of Calgary, Calgary, Alberta, Canada, ³Alberta Children's Hospital, Calgary, Canada, ⁴Alberta Children's Hospital, Calgary, Alberta, Canada, ⁵University of Calgary, Calgary, Canada, ⁶University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada, ⁷Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada
Background/Purpose: Needs assessments have revealed an urgent need for disease information, self-management skills, and peer support for patients with juvenile idiopathic arthritis (JIA). Our aim…
Abstract Number: 029 • 2020 Pediatric Rheumatology Symposium
Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis
Angela Chun¹, Lutfiyya Muhammad ² and Deirdre De Ranieri ³, ¹Lurie Children's Hospital, Chicago, Iowa, ²Northwestern University Feinberg School of Medicine, Chicago, ³Lurie Children's Hospital, Chicago, Illinois
Background/Purpose: The use of intra-articular corticosteroid (IAC) injections for Juvenile Idiopathic Arthritis (JIA) was extrapolated from its use in adult inflammatory joint diseases to achieve…
Abstract Number: 107 • 2020 Pediatric Rheumatology Symposium
Defining the Prevalence of Depression and Anxiety Symptoms in Adolescents with Juvenile Idiopathic Arthritis
Lydia Li¹, Mehveen Merchant ², Shelina Gordon ³, David Lovas ⁴, Joanne Gillespie ⁴, Adam Huber ⁵, Bianca Lang ⁶, Suzanne Ramsey ⁴ and Elizabeth Stringer ⁴, ¹Dalhousie University, Halifax, Canada, ²Calgary, Canada, ³IWK Health Centre, Halifax, ⁴IWK Health Centre, Halifax, Canada, ⁵IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁶Dalhousie University - Halifax, Halifax, Canada
Background/Purpose: We aimed to evaluate the prevalence of depressive and/or anxiety symptoms in adolescents with juvenile idiopathic arthritis (JIA) and explore the association with demographic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].